Literature DB >> 22016501

Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.

Guillaume J Besson, Deborah McMahon, Frank Maldarelli, John W Mellors.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22016501      PMCID： PMC3283111          DOI： 10.1093/cid/cir721

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

2.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

3.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

4.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

5.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

6.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069

7.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823
  7 in total
  23 in total

Review 1.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 2.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

3.  Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Authors:  J E Lake; G A McComsey; T Hulgan; C A Wanke; A Mangili; S L Walmsley; S A Stramotas; R Tracy; J S Currier
Journal:  HIV Med       Date:  2014-02-10       Impact factor: 3.180

4.  Reply to Karch et al.

Authors:  Hiroyu Hatano; Peter Bacchetti; Priscilla Y Hsue; Steven G Deeks
Journal:  J Infect Dis       Date:  2014-01-12       Impact factor: 5.226

5.  Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.

Authors:  Zheng Wang; Evelyn E Gurule; Timothy P Brennan; Jeffrey M Gerold; Kyungyoon J Kwon; Nina N Hosmane; Mithra R Kumar; Subul A Beg; Adam A Capoferri; Stuart C Ray; Ya-Chi Ho; Alison L Hill; Janet D Siliciano; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-26       Impact factor: 11.205

6.  Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.

Authors:  Qingli Niu; Zhiqing Liu; Edrous Alamer; Xiuzhen Fan; Haiying Chen; Janice Endsley; Benjamin B Gelman; Bing Tian; Jerome H Kim; Nelson L Michael; Merlin L Robb; Jintanat Ananworanich; Jia Zhou; Haitao Hu
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

7.  No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

Authors:  Rajesh T Gandhi; Robert W Coombs; Ellen S Chan; Ronald J Bosch; Lu Zheng; David M Margolis; Sarah Read; Beatrice Kallungal; Ming Chang; Erin A Goecker; Ann Wiegand; Mary Kearney; Jeffrey M Jacobson; Richard D'Aquila; Michael M Lederman; John W Mellors; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

Review 8.  Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication.

Authors:  Mudit Tyagi; Michael Bukrinsky
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

9.  Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.

Authors:  Anthony R Cillo; Amrita Krishnan; Ronald T Mitsuyasu; Deborah K McMahon; Shirley Li; John J Rossi; John A Zaia; John W Mellors
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.

Authors:  Anthony R Cillo; Michele D Sobolewski; Ronald J Bosch; Elizabeth Fyne; Michael Piatak; John M Coffin; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.